{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:23:18Z","timestamp":1781796198927,"version":"3.54.5"},"reference-count":31,"publisher":"Becaris Publishing Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison.\n            <jats:bold>Methods:<\/jats:bold>\n            Patients from two phase II\/III trials for erenumab (NCT02066415 and NCT02456740) were pooled and weighted to match on the baseline effect modifiers (age, sex, race, baseline monthly migraine days [MMDs], and history of chronic migraine [CM]) reported in the phase II\/III trial for rimegepant (NCT03732638). Four efficacy outcomes were compared between the two erenumab regimens (70\u00a0mg and 140\u00a0mg) and rimegepant, including changes in MMDs from baseline to month 1 and month 3, changes in Migraine-Specific Quality of Life Questionnaire role function \u2013 restrictive domain score from baseline to month 3, and change in disability from baseline to Month 3.\n            <jats:bold>Results:<\/jats:bold>\n            Compared with rimegepant, erenumab 70\u00a0mg was associated with a statistically significant reduction in MMDs at month 3 (-0.90 [-1.76, -0.03]; p\u00a0=\u00a00.042) and erenumab 140\u00a0mg was associated with statistically significant reductions in MMDs at month 1 (-0.94 [-1.70, -0.19]; p\u00a0=\u00a00.014) and month 3 (-1.28 [-2.17, -0.40]; p\u00a0=\u00a00.005). The erenumab regimens also had numerical advantages over rimegepant for other efficacy outcomes.\n            <jats:bold>Conclusion:<\/jats:bold>\n            In the present study, we found that erenumab had a more favorable efficacy profile than rimegepant in reducing MMDs at month 1 and month 3 for migraine prevention. These results may help with decision-making in clinical practice and can be further validated in future clinical trials or real-world studies.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0122","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T09:48:17Z","timestamp":1704361697000},"source":"Crossref","is-referenced-by-count":6,"title":["Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison"],"prefix":"10.57264","volume":"13","author":[{"given":"Ronan","family":"Mahon","sequence":"first","affiliation":[{"name":"Novartis Ireland Limited, Dublin, D04A9N6, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd, Hyderabad, 500081, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirja","family":"Koch","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, CH-4056, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Ferraris","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, CH-4056, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A","family":"Betts","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, CA 90071, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, CA 90071, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gao","sequence":"additional","affiliation":[{"name":"Analysis Group Inc, Los Angeles, CA 90071, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Proot","sequence":"additional","affiliation":[{"name":"Ghent University Hospital, Ghent, 9000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"10283","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: epidemiology and systems of care","volume":"397","author":"Ashina M","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP Migraine: epidemiology and systems of care. Lancet 397(10283), 1485\u20131495 (2021).","journal-title":"Lancet"},{"issue":"4","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11916-009-0048-3","article-title":"Overuse of acute migraine medications and migraine chronification","volume":"13","author":"Bigal ME","year":"2009","unstructured":"Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr. Pain Headache Rep. 13(4), 301\u2013307 (2009).","journal-title":"Curr. Pain Headache Rep."},{"issue":"8","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study","volume":"48","author":"Bigal ME","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48(8), 1157\u20131168 (2008).","journal-title":"Headache"},{"issue":"1","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0333102413499649","article-title":"Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database","volume":"34","author":"Roberto G","year":"2014","unstructured":"Roberto G, Piccinni C, D'alessandro R, Poluzzi E. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Cephalalgia 34(1), 5\u201313 (2014).","journal-title":"Cephalalgia"},{"issue":"9","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/0333102419835465","article-title":"Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine","volume":"39","author":"Bonafede M","year":"2019","unstructured":"Bonafede M, Wilson K, Xue F. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia 39(9), 1086\u20131098 (2019).","journal-title":"Cephalalgia"},{"issue":"5","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton RB","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5), 343\u2013349 (2007).","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59(1), 1\u201318 (2019).","journal-title":"Headache"},{"key":"e_1_3_8_10_2","unstructured":"AIMOVIG (erenumab-aooe) Food and Drug Administration label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s009lbl.pdf"},{"key":"e_1_3_8_11_2","unstructured":"AJOVY (fremanezumab-vfrm) Food and Drug Administration label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761089s002lbl.pdf"},{"key":"e_1_3_8_12_2","unstructured":"EMGALITY (galcanezumab-gnlm) Food and Drug Administration label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761063s003lbl.pdf"},{"key":"e_1_3_8_13_2","unstructured":"VYEPTI (eptinezumab-jjmr) Food and Drug Administration label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761119s000lbl.pdf"},{"key":"e_1_3_8_14_2","unstructured":"NURTEC ODT (rimegepant) Food and Drug Administration label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212728s006lbl.pdf"},{"key":"e_1_3_8_15_2","unstructured":"QULIPTA (atogepant) Food and Drug Administration label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf"},{"issue":"10268","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase II\/III, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop R","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D Oral rimegepant for preventive treatment of migraine: a phase II\/III, randomised, double-blind, placebo-controlled trial. Lancet 397(10268), 51\u201360 (2021).","journal-title":"Lancet"},{"issue":"22","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby PJ","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 377(22), 2123\u20132132 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper S","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 16(6), 425\u2013434 (2017).","journal-title":"Lancet Neurol."},{"issue":"8","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14712598.2019.1627323","article-title":"Fremanezumab for the preventive treatment of migraine","volume":"19","author":"Silberstein SD","year":"2019","unstructured":"Silberstein SD, Cohen JM, Yeung PP. Fremanezumab for the preventive treatment of migraine. Expert Opin. Biol. Ther. 19(8), 763\u2013771 (2019).","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-018-0951-2","article-title":"Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies","volume":"19","author":"F\u00f6rderreuther S","year":"2018","unstructured":"F\u00f6rderreuther S, Zhang Q, Stauffer VL, Aurora SK, L\u00e1inez MJ. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J. Headache Pain 19(1), 1\u20139 (2018).","journal-title":"J. Headache Pain"},{"issue":"8","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/14712598.2021.1931678","article-title":"Eptinezumab for the treatment of migraine","volume":"21","author":"Spuntarelli V","year":"2021","unstructured":"Spuntarelli V, Negro A, Luciani M, Bentivegna E, Martelletti P. Eptinezumab for the treatment of migraine. Expert Opin. Biol. Ther. 21(8), 999\u20131011 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"issue":"8","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani J","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ Atogepant for the preventive treatment of migraine. N. Engl. J. Med. 385(8), 695\u2013706 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/head.14128","article-title":"Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine","volume":"61","author":"Popoff E","year":"2021","unstructured":"Popoff E, Johnston K, Croop R Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine. Headache 61(6), 906\u2013915 (2021).","journal-title":"Headache"},{"key":"e_1_3_8_24_2","volume-title":"The International Headache Congress \u2013 IHS and EHF Joint Congress.","author":"Silberstein S","year":"2021","unstructured":"Silberstein S, Cohen J, Driessen M Network meta-analysis on monthly migraine day reductions with fremanezumab, rimegepant, and atogepant in the prevention of episodic migraine. Presented at: The International Headache Congress \u2013 IHS and EHF Joint Congress. (2021)."},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0021"},{"key":"e_1_3_8_26_2","unstructured":"Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732638 (2023)."},{"key":"e_1_3_8_27_2","unstructured":"Phillippo D Ades T Dias S Palmer S Abrams KR Welton N. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. (Technical Support Documents). NICE Decision Support Unit (2016)."},{"issue":"1","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s42399-023-01452-w","article-title":"Hellenic Headache Society Recommendations for the use of monoclonal antibodies targeting the calcitonin gene-related peptide pathway for the prevention of migraine and cluster headache \u2013 2023 update","volume":"5","author":"Mitsikostas D","year":"2023","unstructured":"Mitsikostas D, Alexoudi A, Arvaniti C Hellenic Headache Society Recommendations for the use of monoclonal antibodies targeting the calcitonin gene-related peptide pathway for the prevention of migraine and cluster headache \u2013 2023 update. SN Comprehensive Clin. Med. 5(1), 118 (2023).","journal-title":"SN Comprehensive Clin. Med."},{"issue":"4","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/head.14289","article-title":"Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States","volume":"62","author":"Harris L","year":"2022","unstructured":"Harris L, L'italien G, Kumar A Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States. Headache 62(4), 473\u2013481 (2022).","journal-title":"Headache"},{"issue":"1","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20132022 update","volume":"23","author":"Sacco S","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20132022 update. J. Headache Pain 23(1), 1\u201319 (2022).","journal-title":"J. Headache Pain"},{"issue":"6","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/ane.13599","article-title":"Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: a real-life experience in migraine","volume":"145","author":"L\u00f3pez-Bravo A","year":"2022","unstructured":"L\u00f3pez-Bravo A, Oliveros-Cid A, Sevillano-Orte L. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: a real-life experience in migraine. Acta Neurol. Scand. 145(6), 669\u2013675 (2022).","journal-title":"Acta Neurol. Scand."},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0082"},{"issue":"1","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01130-5","article-title":"European headache federation consensus on the definition of resistant and refractory migraine","volume":"21","author":"Sacco S","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A European headache federation consensus on the definition of resistant and refractory migraine. J. Headache Pain 21(1), 1\u201312 (2020).","journal-title":"J. Headache Pain"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T09:56:07Z","timestamp":1709286967000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.57264\/cer-2023-0122"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0122","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"article-number":"e230122"}}